We just received data on a new analyst forecast for $NTRA. Mark Massaro from BTIG set a price target of 210.0 for NTRA.
To track analyst ratings and price targets for $NTRA, check out Quiver Quantitative's $NTRA forecast page.
$NTRA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 9 analysts offer price targets for $NTRA in the last 6 months, with a median target of $210.0.
Here are some recent targets:
- Mark Massaro from BTIG set a target price of $210.0 on 10/23/2025
- Kyle Mikson from Canaccord Genuity set a target price of $200.0 on 10/14/2025
- Brandon Couillard from Wells Fargo set a target price of $175.0 on 09/22/2025
- Mason Carrico from Stephens & Co. set a target price of $183.0 on 08/15/2025
- David Westenberg from Piper Sandler set a target price of $220.0 on 08/11/2025
- Conor McNamara from RBC Capital set a target price of $255.0 on 08/08/2025
- Luke Sergott from Barclays set a target price of $210.0 on 08/08/2025
$NTRA Congressional Stock Trading
Members of Congress have traded $NTRA stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by members of Congress over the last 6 months:
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 3 times. They made 2 purchases worth up to $30,000 on 09/22, 08/22 and 1 sale worth up to $15,000 on 07/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$NTRA Insider Trading Activity
$NTRA insiders have traded $NTRA stock on the open market 181 times in the past 6 months. Of those trades, 0 have been purchases and 181 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 15 sales selling 122,436 shares for an estimated $20,655,165.
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 25 sales selling 68,032 shares for an estimated $10,567,278.
- JONATHAN SHEENA has made 0 purchases and 66 sales selling 44,024 shares for an estimated $7,358,215.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 8 sales selling 26,187 shares for an estimated $4,349,333.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 28 sales selling 25,519 shares for an estimated $3,934,581.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 18 sales selling 16,747 shares for an estimated $2,496,700.
- GAIL BOXER MARCUS has made 0 purchases and 13 sales selling 14,795 shares for an estimated $2,316,079.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 7 sales selling 6,213 shares for an estimated $941,038.
- ROWAN E CHAPMAN sold 2,750 shares for an estimated $459,222
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NTRA Hedge Fund Activity
We have seen 368 institutional investors add shares of $NTRA stock to their portfolio, and 270 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 3,263,822 shares (+44.3%) to their portfolio in Q2 2025, for an estimated $551,390,088
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,650,073 shares (+15.7%) to their portfolio in Q2 2025, for an estimated $278,763,332
- CITADEL ADVISORS LLC removed 1,301,513 shares (-61.3%) from their portfolio in Q2 2025, for an estimated $219,877,606
- KYNAM CAPITAL MANAGEMENT, LP removed 1,167,570 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $197,249,275
- CAPITAL WORLD INVESTORS added 1,013,229 shares (+255.6%) to their portfolio in Q2 2025, for an estimated $171,174,907
- LORD, ABBETT & CO. LLC removed 736,644 shares (-48.4%) from their portfolio in Q2 2025, for an estimated $124,448,637
- POINTSTATE CAPITAL LP removed 615,287 shares (-81.4%) from their portfolio in Q2 2025, for an estimated $103,946,585
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
